Preoperative <i>H. pylori</i> Eradication Therapy Facilitates Precise Delineation in Early Gastric Cancer with Current <i>H. pylori</i> Infection
-
Published:2023-10-13
Issue:1
Volume:42
Page:1-11
-
ISSN:0257-2753
-
Container-title:Digestive Diseases
-
language:en
-
Short-container-title:Dig Dis
Author:
Yan Zhiyu,Zou Long,Wang Qiang,Zhang Shengyu,Jiao Yuhao,Xiong Dingkun,Jiang Qingwei,Guo Tao,Feng Yunlu,Wu Dongsheng,Lai Yamin,Yan Xuemin,Xu Tao,Fang Weigang,Wu Xi,Zhou Weixun,Yang Aiming
Abstract
<b><i>Introduction:</i></b> Early gastric cancer with current <i>Helicobacter pylori</i> infection (<i>Hp</i>C-EGC) is common, but it is still unclear whether <i>H. pylori</i> eradication therapy (<i>Hp</i>-ET) or endoscopic submucosal dissection (ESD) should be performed first. We evaluated <i>Hp</i>-ETs short-term effects on horizontal boundary delineations of <i>Hp</i>C-EGC in ESD. <b><i>Methods:</i></b> Prospectively enrolled <i>Hp</i>C-EGC patients were randomly assigned to eradication or control groups. Operation scopes of <i>Hp</i>C-EGC lesions were delineated with marking dots at 5 mm out of the endoscopic demarcation line by an independent endoscopist, unaware of eradication status, before formal circumferential incision. As representatives, precise delineation rate, the shortest distance of all marking dots to the pathological demarcation line in all slices of one intact resected specimen (D<sub>min</sub>), and negative marking dot specimen rate were examined. <b><i>Results:</i></b> Twenty-three <i>Hp</i>C-EGC patients (25 lesions) were allocated to eradication group and 26 patients (27 lesions) were allocated to the control group with similar eradication success rates and all were differentiated type. With improving background mucosa inflammation after <i>Hp</i>-ET and similar gastritis-like epithelium rates, 10 lesions (40.0%) in the eradication group were of precise delineation compared to control group with 2 lesions (7.4%) (relative risk = 5.40, 95% CI 1.31–22.28). D<sub>min</sub> of eradication and control groups were 4.17 ± 2.52 mm and 2.67 ± 2.30 mm (<i>p</i> = 0.029), accompanied by 4 (14.8%) and none (0.0%) specimens that exhibited positive marking dots (<i>p</i> = 0.11), respectively. <b><i>Conclusion:</i></b> For <i>Hp</i>C-EGC patients, administrating eradication medication before ESD is beneficial for the precise delineation of lesions and reducing the risk of positive horizontal resection margins.
Subject
Gastroenterology,General Medicine